Using a risk score to guide treatment for newly diagnosed myeloma with +1q
Studies a risk-scoring tool to guide treatment in people newly diagnosed with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Risk-adapted Therapeutic Strategy in +1q NDMM
Key facts
- Where
- Changchun, ChinaSee the site
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- FengYan Jin
- Trial code
- NCT07045168
- Record updated
- 15 September 2025
- Original description
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.Read full original descriptionShow less
Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.
Inclusion: Age >=18, or >=65 and fit according to IMWG-FI; Newly diagnosed NDMM by 2014 IMWG criteria; Adequate organ function for systemic therapy; Signed informed consent.
Exclusion: History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years; Active infections requiring systemic treatment; Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias; Current malignancies requiring therapy; Refusal to participate.